AI-generated summary
The authors report two cancer patients who developed severe, long-lasting painful oral mucositis during pembrolizumab immunotherapy, with ulcerations persisting over 30 weeks in total and more than 16 weeks after stopping treatment. In one patient, pain relief was achieved with low-level laser photobiomodulation. The study is a retrospective chart review of only two patients, so the findings are limited in scope.
- Participants
- 2
- Who or what was studied
- Two male cancer patients treated with pembrolizumab, one for anaplastic astrocytoma and one for lung adenocarcinoma, who developed oral mucositis during immunotherapy.
- Limits stated in the abstract
- The report is a retrospective review of only two patients, so no general conclusions can be drawn about frequency or outcomes, and the photobiomodulation result applies to a single patient.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Oral mucositis, Photobiomodulation, GRADE, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.